Literature DB >> 27220665

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

S Schliffke1, N Akyüz1, C T Ford1, T Mährle1, T Thenhausen2, A Krohn-Grimberghe2, S Knop3, C Bokemeyer1, M Binder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27220665     DOI： 10.1038/leu.2016.157

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells.

Authors:  Sarka Ruzickova; Axel Pruss; Marcus Odendahl; Karsten Wolbart; Gerd-Rüdiger Burmester; Jürgen Scholze; Thomas Dörner; Arne Hansen
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

2.  Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

Authors:  F R Mauro; R Foa; R Cerretti; D Giannarelli; S Coluzzi; F Mandelli; G Girelli
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

3.  Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Candida Vitale; Inhye E Ahn; Mariela Sivina; Alessandra Ferrajoli; William G Wierda; Zeev Estrov; Sergej N Konoplev; Nitin Jain; Susan O'Brien; Mohammed Farooqui; Michael J Keating; Adrian Wiestner; Jan A Burger
Journal:  Haematologica       Date:  2016-03-24       Impact factor: 9.941

4.  Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance.

Authors:  Carol Moreno; Kate Hodgson; Gerardo Ferrer; Montse Elena; Xavier Filella; Arturo Pereira; Tycho Baumann; Emili Montserrat
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

5.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

6.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

7.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

8.  Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells.

Authors:  Andrew M Hall; Mark A Vickers; Ewan McLeod; Robert N Barker
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

9.  Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Authors:  K A Rogers; A S Ruppert; A Bingman; L A Andritsos; F T Awan; K A Blum; J M Flynn; S M Jaglowski; G Lozanski; K J Maddocks; J C Byrd; J A Woyach; J A Jones
Journal:  Leukemia       Date:  2015-10-07       Impact factor: 11.528

Review 10.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388
View more
  10 in total

1.  Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Authors:  Paul J Hampel; Melissa C Larson; Brian Kabat; Timothy G Call; Wei Ding; Saad S Kenderian; Deborah Bowen; Justin Boysen; Susan M Schwager; Jose F Leis; Asher A Chanan-Khan; Eli Muchtar; Curtis A Hanson; Susan L Slager; Neil E Kay; Kari G Chaffee; Tait D Shanafelt; Sameer A Parikh
Journal:  Br J Haematol       Date:  2018-08-16       Impact factor: 6.998

2.  T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors.

Authors:  Donjete Simnica; Nuray Akyüz; Simon Schliffke; Malte Mohme; Lisa V Wenserski; Thorben Mährle; Lorenzo F Fanchi; Katrin Lamszus; Mascha Binder
Journal:  Oncoimmunology       Date:  2019-07-25       Impact factor: 8.110

3.  Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Authors:  Simon Schliffke; Mariela Sivina; Ekaterina Kim; Lisa von Wenserski; Benjamin Thiele; Nuray Akyüz; Clemens Falker-Gieske; Donjete Statovci; Anna Oberle; Toni Thenhausen; Artus Krohn-Grimberghe; Carsten Bokemeyer; Nitin Jain; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Michael Keating; Jan A Burger; Mascha Binder
Journal:  Oncoimmunology       Date:  2018-01-15       Impact factor: 8.110

4.  Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.

Authors:  Anna Oberle; Anna Brandt; Minna Voigtlaender; Benjamin Thiele; Janina Radloff; Anita Schulenkorf; Malik Alawi; Nuray Akyüz; Manuela März; Christopher T Ford; Artus Krohn-Grimberghe; Mascha Binder
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941

5.  Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

Authors:  M Montillo; S O'Brien; A Tedeschi; J C Byrd; C Dearden; D Gill; J R Brown; J C Barrientos; S P Mulligan; R R Furman; F Cymbalista; C Plascencia; S Chang; E Hsu; D F James; P Hillmen
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037

6.  Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Authors:  Thorben Mährle; Nuray Akyüz; Pim Fuchs; Nicola Bonzanni; Donjete Simnica; Ulrich Germing; Anne Marie Asemissen; Johann Christoph Jann; Florian Nolte; Wolf-Karsten Hofmann; Daniel Nowak; Mascha Binder
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

7.  Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.

Authors:  Juliane Grimm; Donjete Simnica; Nadja Jäkel; Lisa Paschold; Edith Willscher; Susann Schulze; Christine Dierks; Haifa Kathrin Al-Ali; Mascha Binder
Journal:  Blood Cancer J       Date:  2022-01-28       Impact factor: 11.037

8.  High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias.

Authors:  Donjete Simnica; Simon Schliffke; Christoph Schultheiß; Nicola Bonzanni; Lorenzo F Fanchi; Nuray Akyüz; Barbara Gösch; Christian Casar; Benjamin Thiele; Janina Schlüter; Ansgar W Lohse; Mascha Binder
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

9.  Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.

Authors:  Meijing Liu; Xuelin Wang; Zheng Li; Rui Zhang; Juan Mu; Yanyu Jiang; Qi Deng; Lei Sun
Journal:  Cancer Sci       Date:  2020-09-15       Impact factor: 6.716

10.  PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.

Authors:  Alexander Stein; Donjete Simnica; Christoph Schultheiß; Rebekka Scholz; Joseph Tintelnot; Eray Gökkurt; Lisa von Wenserski; Edith Willscher; Lisa Paschold; Markus Sauer; Sylvie Lorenzen; Jorge Riera-Knorrenschild; Reinhard Depenbusch; Thomas J Ettrich; Steffen Dörfel; Salah-Eddin Al-Batran; Meinolf Karthaus; Uwe Pelzer; Lisa Waberer; Axel Hinke; Marcus Bauer; Chiara Massa; Barbara Seliger; Claudia Wickenhauser; Carsten Bokemeyer; Susanna Hegewisch-Becker; Mascha Binder
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.